Zevra Therapeutics (NASDAQ:ZVRA) Announces Quarterly Earnings Results

Key Points

• Zevra Therapeutics reported a quarterly EPS of ($0.06), missing the consensus estimate by ($0.71).
• The company's stock traded up $0.06 to hit $11.76, with a market capitalization of $643.04 million.
• Despite the earnings miss, several analysts have given Zevra a buy rating, with a consensus target price of $23.71.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) released its earnings results on Tuesday. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of $1.43 by ($1.49), Zacks reports. The business had revenue of $25.88 million during the quarter, compared to the consensus estimate of $22.49 million. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA traded up $0.53 on Friday, hitting $9.43. The company's stock had a trading volume of 2,797,692 shares, compared to its average volume of 1,477,849. The company has a market capitalization of $529.31 million, a PE ratio of -44.90 and a beta of 1.87. The company has a debt-to-equity ratio of 0.52, a current ratio of 7.85 and a quick ratio of 7.81. Zevra Therapeutics has a 1 year low of $6.19 and a 1 year high of $13.16. The company has a 50-day simple moving average of $10.56 and a 200 day simple moving average of $8.77.

Institutional Investors Weigh In On Zevra Therapeutics

A number of large investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Zevra Therapeutics by 6.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock worth $238,000 after purchasing an additional 1,812 shares during the last quarter. Strs Ohio bought a new stake in Zevra Therapeutics during the first quarter valued at about $125,000. Creative Planning bought a new stake in Zevra Therapeutics during the second quarter valued at about $92,000. Rhumbline Advisers grew its holdings in Zevra Therapeutics by 11.6% during the second quarter. Rhumbline Advisers now owns 83,221 shares of the company's stock valued at $733,000 after purchasing an additional 8,636 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Zevra Therapeutics during the second quarter valued at about $255,000. 35.03% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ZVRA has been the subject of several recent research reports. JMP Securities decreased their target price on shares of Zevra Therapeutics from $19.00 to $18.00 and set a "market outperform" rating for the company in a research report on Wednesday. Cantor Fitzgerald increased their price objective on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday. Wall Street Zen downgraded shares of Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 20th. Finally, HC Wainwright started coverage on shares of Zevra Therapeutics in a report on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $23.71.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.